Back to Search
Start Over
Treatment adherence in tyrosinemia type 1 patients
- Source :
- Orphanet Journal of Rare Diseases, Orphanet journal of rare diseases (2021) 16:256, UCrea Repositorio Abierto de la Universidad de Cantabria, Universidad de Cantabria (UC), Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-9 (2021)
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Background While therapeutic advances have significantly improved the prognosis of patients with hereditary tyrosinemia type 1 (HT1), adherence to dietary and pharmacological treatments is essential for an optimal clinical outcome. Poor treatment adherence is well documented among patients with chronic diseases, but data from HT1 patients are scarce. This study evaluated pharmacological and dietary adherence in HT1 patients both directly, by quantifying blood levels nitisinone (NTBC) levels and metabolic biomarkers of HT1 [tyrosine (Tyr), phenylalanine (Phe), and succinylacetone]; and indirectly, by analyzing NTBC prescriptions from hospital pharmacies and via clinical interviews including the Haynes–Sackett (or self-compliance) test and the adapted Battle test of patient knowledge of the disease. Results This observational study analyzed data collected over 4 years from 69 HT1 patients (7 adults and 62 children; age range, 7 months–35 years) who were treated with NTBC and a low-Tyr, low-Phe diet. Adherence to both pharmacological and, in particular, dietary treatment was poor. Annual data showed that NTBC levels were lower than recommended in more than one third of patients, and that initial Tyr levels were high (> 400 µM) in 54.2–64.4% of patients and exceeded 750 µM in 25.8% of them. Remarkably, annual normalization of NTBC levels was observed in 29.4–57.9% of patients for whom serial NTBC determinations were performed. Poor adherence to dietary treatment was more refractory to positive reinforcement: 36.2% of patients in the group who underwent multiple analyses per year maintained high Tyr levels during the entire study period, and, when considering each of the years individually this percentage ranged from 75 to 100% of them. Indirect methods revealed percentages of non-adherent patients of 7.3 and 15.9% (adapted Battle and Haynes tests, respectively). Conclusions Despite initially poor adherence to pharmacological and especially dietary treatment among HT1 patients, positive reinforcement at medical consultations resulted in a marked improvement in NTBC levels, indicating the importance of systematic positive reinforcement at medical visits.
- Subjects :
- Adult
medicine.medical_specialty
Adolescent
Nitisinone
Treatment adherence
Phenylalanine
Disease
Tyrosinemia
Young Adult
03 medical and health sciences
0302 clinical medicine
Refractory
Internal medicine
Tyrosinemia type 1
Humans
Medicine
Pharmacology (medical)
030212 general & internal medicine
Medical prescription
Child
Genetics (clinical)
Cyclohexanones
Tyrosinemias
business.industry
Research
Infant
General Medicine
Prognosis
medicine.disease
Diet
Treatment Adherence and Compliance
Succinylacetone
Adherence
Child, Preschool
Nitrobenzoates
Tyrosine
Observational study
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 17501172
- Volume :
- 16
- Database :
- OpenAIRE
- Journal :
- Orphanet Journal of Rare Diseases
- Accession number :
- edsair.doi.dedup.....dc3589a59d4251a202c992ab7c5a2982
- Full Text :
- https://doi.org/10.1186/s13023-021-01879-1